Under the terms of the amended agreement, Predix may be eligible for up to an additional $3.5 million in research funding and milestone payments, bringing the total value of its research collaboration with the foundation to $16 million.
In addition, Predix has achieved another milestone under the original agreement and will receive the associated $1.5 million payment.
“We are very pleased that we are now at the point where Predix can begin conducting drug discovery research based on its innovative computer model of the cystic fibrosis protein CFTR,” said Dr Robert Beall, president and CEO of the Cystic Fibrosis Foundation. “We look forward to continuing to work together and are hopeful that the Predix team will identify compounds that could become new potential therapies for people with cystic fibrosis.”